Brief: I-Mab Announces Givastomig Abstract Accepted For Oral Presentation At ESMO GI 2025
30/04/2025 12:12
April 30 (Reuters) - I-Mab IMAB.O: I-MAB ANNOUNCES GIVASTOMIG ABSTRACT ACCEPTED FOR ORAL PRESENTATION AT ESMO GI 2025 Source text: ID:nGNX3Vz1fh Further company coverage: IMAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview